TNF and Cowden disease: To the best of our knowledge, this was the first multicenter, prospective, open-label study in Latin America providing in-depth insight into the safety profile and effectiveness of ustekinumab in patients with moderate-to-severe CD who were refractory to anti-TNF-α agents and conventional drugs.